Medical Policy Testosterone Therapy

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Medical Policy Testosterone Therapy"

Transcription

1 Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet are forms of testosterone injection used to treat symptoms of low testosterone in men who do not produce enough natural testosterone. Testosterone enanthate and testosterone pellet are also used to stimulate puberty in males with delayed puberty. Testosterone is a hormone produced by the body that contributes to the growth, development, and functioning of the male sexual organs and typical male characteristics. Testosterone injection works by supplying synthetic testosterone to replace the testosterone that is normally produced naturally in the body. Policy and Coverage Criteria: Harvard Pilgrim considers injectable/infusible testosterone and testosterone implants medically necessary to treat low testosterone caused by: Primary or secondary hypogonadism; Human Immunodeficiency Virus; High-dose glucocorticoids Harvard Pilgrim considers injectable/infusible testosterone medically necessary for members with metastatic breast cancer. Harvard Pilgrim considers injectable/infusible testosterone and testosterone implants medically necessary for transgender members. Exclusions: HPHC does not cover testosterone therapy for conditions not outlined above. Supporting Information: 1. Technology Assessment: Testosterone cypionate, testosterone enanthate, and testosterone undecanoate injection come as a solution that is injected into the muscle. Testosterone injection may also come as a pellet that is injected under the skin. According to the prescribing information for Testopel: TESTOPEL Pellets (testosterone) are cylindrically shaped pellets 3.2mm (1/8 inch) in diameter and approximately 9mm in length. Each sterile pellet weighs approximately 78mg (75mg testosterone) and is ready for implantation INDICATIONS AND USAGE: Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a) Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b) Hypogonadotrophic hypogonadism (congenital or acquired) - idiopathic or gonadotropic LHRH deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. 2. Literature Review: In their update on diagnosis and treatment of male hypogondaism, Darby and Anawalt (2005) list the potential benefits of androgen replacement therapy as: improved sexual function, enhanced sense of well-being, increased lean body mass, decreased body fat, and increased bone density. Weekly-to-biweekly injections of testosterone cypionate (cipionate) or testosterone enanthate (enantate) are widely used, as they are economical and generally

2 well tolerated. Intramuscular injection of testosterone undecanoate is an attractive newer therapy that can be administered quarterly. Haider et al. (2015) conducted an analysis of 3 parallel, prospective, ongoing, cumulative registry studies including 1,023 hypogonadal men who received testosterone therapy. Patients were treated when total testosterone was 12.1 nmol/l or less (350 ng/dl) and symptoms of hypogonadism were present. Maximum followup was 17 years (1996 to 2013) and median follow-up was 5 years. Patients received testosterone undecanoate injections in 12-week intervals. A total of 11 patients were diagnosed with prostate cancer in the 2 urology settings at proportions of 2.3% and 1.5%, respectively. The incidence per 10,000 patient-years was 54.4 and 30.7, respectively. No prostate cancer was reported by the andrology center. The authors concluded that testosterone therapy in hypogonadal men does not increase the risk of prostate cancer. If guidelines for testosterone therapy are properly applied, testosterone treatment is safe in hypogonadal men. Conaglen et al. (2014) retrospectively assessed the efficacy and safety of long-term testosterone undecanoate depot (TUD) therapy in the clinical setting and compare TUD with T pellet implants. Data was collected for 179 hypogonadal men treated with TUD for 2 years. 72% of trough total testosterone (TT) levels were in the normal range for TUD therapy compared with 53% of trough TT levels during TI therapy. TUD therapy was well tolerated with 162 men completing 2 years of treatment, and only seven men stopping TUD because of adverse effects. A rise in Hb and/or Hct occurred in 25 men, and a significant rise in PSA in 20 men at some stage during TUD therapy. At 2 years, 91% of men received the standard 1,000 mg TUD dose with 66% at the standard dosing interval of weekly. The authors concluded that TUD is an efficacious, safe, and well tolerated. Yassin et al. (2014) investigated whether treatment with testosterone undecanoate (TU) has a long-term and sustained effect on metabolic syndrome in men with late-onset hypogonadism and erectile dysfunction, to determine whether long-term testosterone treatment can improve overall health-related quality of life, and to establish the safety of long-term testosterone treatment. A prospective, observational, and longitudinal registry study including 261 patients diagnosed with late-onset hypogonadism and ED were treated with long-acting TU were analyzed. The men received intramuscular injections of 1,000 mg TU at day 1, week 6, and every 3 months thereafter. A significant improvement in obesity parameters and lowered total cholesterol, LDL cholesterol, triglycerides, fasting blood glucose, HbA1c, and blood pressure over the 5-year study were found. HDL cholesterol was increased. Sustained improvement in erectile function and muscle and joint pain, which contributed to an improvement in long-term health-related quality of life was found. There was no evidence that long-term treatment with TU increases the risk of prostate carcinoma. The authors concluded that long-term TU in men with late-onset hypogonadism and ED reduces obesity parameters and improves metabolic syndrome and health-related quality of life. Corona et al. (2014) conducted a meta-analysis of available evidence to assess the efficacy and safety of injectable testosterone undecanoate (TU). Injectable TU was significantly associated with a reduction of fat mass and HbA1c in both controlled and uncontrolled trials, in particular when hypogonadal subjects were enrolled. Similar results were observed for the improvement of erectile function. In addition, TU ameliorated several other outcomes, including blood pressure, lipid profile, waist circumference and body mass index in uncontrolled studies, but these data were not confirmed in placebo-controlled trials. The treatment was well tolerated and no risk of prostate cancer or cardiovascular disease was observed. The authors conclude that injectable TU is a safe and effective treatment for male HG. The possibility of a therapeutic intervention just four to five times per year frees the patient, at least partially, from having a chronic condition, thus maintaining a positive, active role in selfcaring. Zitzmann et al. (2013) assessed the safety and efficacy of injectable long-acting TU in hypogonadal men in daily clinical practice. A total of 1,438 patients who received TU were enrolled and analyzed. Scores of mental and psychosexual functions improved markedly, while mean waist circumference decreased from 100 to 96 cm. Blood pressure and lipid parameters were altered in a favorably and significantly. After four TU injection intervals, the percentage of patients with "low" or "very low" levels of sexual desire/libido decreased from 64% at baseline to 10%; moderate, severe, or extremely severe erectile dysfunction decreased from 67% to 19%. At the last observation, 89% of patients were "satisfied" or "very satisfied" with TU therapy. Adverse events and adverse drug reactions (ADRs) occurred in 12% and 6% of patients, respectively, mostly mild to moderate. The most common ADRs were increase in hematocrit, increase in PSA, and injection site pain (all <1%). No case of prostate cancer was observed. The authors concluded that injectable long-acting TU is effective and well tolerated. Jockenhovel et al. (2009) compared the effects of testosterone enanthate (TE) versus TU on sexual functioning and mood in 40 hypogonadal men over a period of 30 weeks. Both groups showed significant and similar

3 improvements in the sexual functioning variables. The authors concluded that both TE and TU are effective in improving sexual functions in hypogonadal men. Additionally, an advantage of TU over TE is the lower frequency of administration and its better tolerability and safety profile. Rabkin et al. (2000) evaluated the efficacy of testosterone in alleviation of hypogonadal symptoms in 70 men with symptomatic human immunodeficiency virus illness. A double-blind, placebo-controlled 6-week trial enrolled was conducted and patients received bi-weekly testosterone injections, followed by 12 weeks of open-label maintenance treatment. Response rates, defined as much or very much improved libido, were 74% for patients randomized to testosterone, and 19% for placebo-treated patients. Of the 62 patients with fatigue at baseline, 59% receiving testosterone and 25% receiving placebo reported improved energy. Among the 26 patients with an Axis I depressive disorder at baseline, 58% of the testosterone-treated patients reported improved mood compared with 14% of placebo-treated patients. With testosterone treatment, average increase in muscle mass over 12 weeks was 1.6 kg for the whole group, and 2.2 kg for the 14 men with wasting at baseline. Improvement on all parameters was maintained during subsequent open-label treatment for up to 18 weeks. The authors concluded that testosterone was well tolerated and effective in the short-term treatment of symptoms of clinical hypogonadism in men with symptomatic HIV illness, restoring libido and energy, alleviating depressed mood, and increasing muscle mass. Bhasin et al. (1997) conducted a study to determine the effects of testosterone enanthate (100 mg/week im injections for 10 weeks) on body composition in seven hypogonadal men. Body weight, fat-free mass measured by underwater weighing and deuterated water dilution, and muscle size measured by MRI were assessed before and after treatment. Energy and protein intake were standardized at 35 Cal/kg per day. Body weight increased significantly from after 10 weeks of testosterone replacement therapy. Fat-free mass, measured by underwater weighing, increased, but percent fat did not significantly change. Similar increases in fat-free mass were observed with the deuterated water method. Muscle strength, assessed by one repetition maximum of weight-lifting exercises increased significantly after testosterone treatment. There was no significant change in hemoglobin, hematocrit, creatinine, and transaminase levels. The authors concluded that replacement doses of testosterone increase fat-free mass and muscle size and strength in hypogonadal men. Behre et al. (1997) studied bone mineral density (BMD) in 72 hypogonadal patients (37 men with primary and 35 men with secondary hypogonadism) under testosterone therapy that continued for up to 16 years. At annual intervals, trabecular BMD of the lumbar spine was measured by quantitative computed tomography. Serum levels of testosterone increased to the normal range in all androgen-treated hypogonadal men. The most significant increase in BMD was seen during the first year of testosterone treatment in previously untreated patients. Long term testosterone treatment maintained BMD in the age-dependent reference range in all 72 hypogonadal men, independent of the type of hypogonadism. Transdermal testosterone patches applied to the scrotum were as effective in normalizing BMD as testosterone enanthate injections. The authors concluded that testosterone therapy increases BMD in hypogonadal men regardless of age. The greatest increase is seen during the first year of treatment in previously untreated patients with low initial BMD. In hypogonadal men, BMD can be normalized and maintained in the normal range by continuous, long term testosterone substitution. 3. Professional/Governmental Organizations: The Endocrine Society: Clinical Practice Guideline for Testosterone Therapy: We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. We suggest the measurement of morning total testosterone level by a reliable assay as the initial diagnostic test. We recommend confirmation of the diagnosis by repeating the measurement of morning total testosterone and, in some men in whom total testosterone is near the lower limit of normal or in whom SHBG abnormality is suspected by measurement of free or bioavailable testosterone level, using validated assays. We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. We recommend against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 4 ng/ml or greater than 3 ng/ml in men at high risk for prostate cancer such as African-Americans or men with first-degree relatives with prostate cancer without further urological evaluation, hematocrit greater than 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate Symptom Score above 19, or uncontrolled or poorly controlled heart failure. When testosterone therapy is instituted, we suggest aiming at achieving testosterone levels during treatment in the mid-normal range with any of the approved

4 formulations, chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. Men receiving testosterone therapy should be monitored using a standardized plan. Coding: Codes are listed below for informational purposes only, and do not guarantee member coverage or provider reimbursement. The list may not be all-inclusive. HCPCS Description Code J1071 J3121 J3145 References: Injection, testosterone cypionate, 1 mg Injection, testosterone enanthate, 1 mg Injection, testosterone undecanoate, 1 mg 1. Hayes, Inc. Search and Summary. Testopel (Auxilium Pharmaceuticals Inc.) Implantable Testosterone Pellet for Hypogonadism. Lansdale, PA: Hayes, Inc. November 13, Snyder, PJ. Testosterone treatment of male hypogonadism. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA. (Accessed February 5, 2015). 3. Ellis, M., Naughton, MJ., Ma, CX. Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA. (Accessed February 5, 2015). 4. Testosterone Injection. U.S. National Library of Medicine, Bethesda, MD. U.S. Department of Health and Human Services National Institutes of Health. Page last updated: 26 January Accessed February 12, Bhasin, S., Cunningham, GR., Hayes, FJ., Matsumoto, AM., Snyder, PJ., Swerdloff, RS., Montori, VM.;Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6): Behre, HM., Kliesch, S., Leifke, E., Link, TM., Nieschlaq, E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metabol. 1997; 82(8): Corona, G., Maseroli, E., Maggi, M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014; 15(13): Haider, A., Zitzmann, M., Doros, G., Isbarn, H., Hammerer, P., Yassin, A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol. 2015; 193(1): Yassin, DJ., Doros, G., Hammerer, PG., Yassin, AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014; 11(6): Conaglen, HM., Paul, RG., Yarndley, T., Kamp, J., Elston, MS., Conaglen, JV. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. J Sex Med. 2014; 11(2): Zitzmann, M., Mattern, A., Hanisch, J., Gooren, L., Jones, H., Maggi, M. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in the worldwide sample of 1,438 men. J Sex Med. 2013; 10(2): Jockenhovel, F., Minnemann, T., Schubert, M., Freud, S., Hubler, D., Schumann, C., Christoph, A., Ernst, M. Comparison of long-acting testosterone undecanoate versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol. 2009; 160(5): Darby, E., Anawalt, BD. Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol. 2005; 4(5): Bhasin, S., Storer, TW., Berman, N., Yarasheski, KE., Clevenger, B., Phillips, J., Lee, WP., Bunnell, TJ., Casaburi, R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997; 82(2): Rabkin, JG., Wagner, GJ., Rabkin, R. A double-blind, placebo-controlled trial of testosterone therapy for HIVpositive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000; 57(2):141-7.

5 Summary of Changes Date Revisions 5/17 Removed Deleted HCPCS codes and Benchmarks Approved by UMCPC: 5/10/17

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through

More information

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through

More information

Issues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options

Issues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing

More information

Insight into male menopause'

Insight into male menopause' Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,

More information

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL.

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL. Generic Brand HICL GCN Exception/Other ANDRODERM 01403 ROUTE MISCELL. ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO DEPO- 01400 ROUTE MISCELL. CYPIONATE TESTOSTERON E GCN 38586 DELATESTRYL 01401

More information

Testosterone Topical/Buccal/Nasal

Testosterone Topical/Buccal/Nasal BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

Current Data and Considerations Novel Testosterone Formulations

Current Data and Considerations Novel Testosterone Formulations Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review

More information

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred

More information

Medication Policy Manual

Medication Policy Manual Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Non-preferred, non-transdermal testosterone replacement therapy products (Android, Aveed, Androxy, Methitest,

More information

Jeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017

Jeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017 Jeremiah Murphy, MD Mercy Urology Clinic October 21, 2017 Describe an appropriate strategy for the evaluation and diagnosis of male hypogonadism Endocrine Society Clinical Practice Guideline-2010 Review

More information

September 17, FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT):

September 17, FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT): JOINT MEETING FOR BONE, REPRODUCTIVE AND UROLOGIC DRUGS ADVISORY COMMITTEE (BRUDAC) AND THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE (DSARM AC) September 17, 2014 FDA background documents for

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Policy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor.

Policy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor. Injectablee Testosterone Products Prior Authorization Policy Number: 5.01.597 Origination: 07/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for injectable testosterone

More information

Natural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone

Natural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured

More information

Chapter 5. General discussion

Chapter 5. General discussion Chapter 5. General discussion 127 Chapter 5 In 2003, two review papers concluded that endogenous androgens do not show any consistent association with cardiovascular disease (CVD) risk 1,2. Apparently,

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Implantable Hormone Pellets Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...

More information

ANDROGENS PLAY AN essential role in the sexual

ANDROGENS PLAY AN essential role in the sexual 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone

More information

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc. GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN

More information

TREATMENT OPTIONS FOR MALE HYPOGONADISM

TREATMENT OPTIONS FOR MALE HYPOGONADISM TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,

More information

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate) PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of

More information

PHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor

PHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme

More information

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM 750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride

More information

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride 1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride

More information

PRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)

PRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate) PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone

More information

DEPO-Testosterone Injection is available in two strengths, 100 mg/ml and 200 mg/ml testosterone cypionate.

DEPO-Testosterone Injection is available in two strengths, 100 mg/ml and 200 mg/ml testosterone cypionate. Depo -Testosterone testosterone cypionate injection, USP CIII DESCRIPTION DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate

More information

Male Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2

Male Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2 Male Hormone Replacement Therapy Punita Dhindsa D.O PGY 2 Physiology of Testosterone & Causes of Hypogonadism in Males The use of testosterone therapy is very common in the US, with an estimated 2.3 million

More information

Clinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일

Clinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일 Clinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일 Development of 5ARI Discovery of 5AR type I and type II Pharmacodynamic and pharmacokinetic

More information

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred Topical Androgen Criteria Program Summary

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred Topical Androgen Criteria Program Summary OBJECTIVE The intent of the Androgens and Anabolic Steroids Prior Authorization with Quantity Limit (PA) program is to appropriately select patients for therapy according to product labeling and/or clinical

More information

HGH for Sale Natural Anti-Aging Human Growth Hormone

HGH for Sale Natural Anti-Aging Human Growth Hormone HGH for Sale Natural Anti-Aging Human Growth Hormone Human growth hormone is one of the hottest supplement trends on the market, and now you can purchase top-quality HGH to be delivered right to your home!

More information

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains

More information

Icd-10 low levels of testosterone

Icd-10 low levels of testosterone Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases

More information

PRODUCT INFORMATION PROVIRON

PRODUCT INFORMATION PROVIRON PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5

More information

Female testosterone level chart

Female testosterone level chart Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9

More information

Growth Hormone & Somatotropin are an Ergogenic Aid

Growth Hormone & Somatotropin are an Ergogenic Aid Growth Hormone & Somatotropin are an Ergogenic Aid BPK 312 MARCH 28 2017 MICHAEL MORKOS PAUL SOURIAL DEL INGVALDSON Table of Contents 1. Hypothesis 2. Clinical Use 3. Mechanism of Action 4. Growth hormone

More information

Testosterone Use and Effects

Testosterone Use and Effects Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).

More information

The Science of. NUTRICULA Longevity Journal

The Science of. NUTRICULA Longevity Journal 32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,

More information

DUPROST Capsules (Dutasteride)

DUPROST Capsules (Dutasteride) Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride

More information

Testosterone Replacement Therapy

Testosterone Replacement Therapy 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca Testosterone Replacement Therapy Environmental Scan and Local/Historical Context December 1, 2014 2 Executive Summary Part A: Pharmacy Benefit

More information

PRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl

PRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl PRODUCT INFORMATION SUSTANON '250' NAME OF THE MEDICINE Sustanon '250' ('250' mg/ml for injection): testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate.

More information

Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism

Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism Brigham Young University BYU ScholarsArchive All Student Publications 2016-07-27 Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism Christopher M. Williams Brigham

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218

More information

AndroGel. (testosterone gel) 1% H 3 C

AndroGel. (testosterone gel) 1% H 3 C 1 AndroGel (testosterone gel) 1% 500122/500127 Rev Dec 2004 DESCRIPTION AndroGel (testosterone gel) is a clear, colorless hydroalcoholic gel containing 1% testosterone. AndroGel provides continuous transdermal

More information

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Andriol Testocaps, Sustanon and Testosterone Implants [] NL/W/0026/pdWS/001

More information

Transsexuals and competitive sports

Transsexuals and competitive sports European Journal of Endocrinology (2004) 151 425 429 ISSN 0804-4643 REVIEW Transsexuals and competitive sports Louis J G Gooren and Mathijs C M Bunck Department of Endocrinology, Section of Andrology,

More information

Pathways and manipulation of testosterone biosynthesis and metabolism

Pathways and manipulation of testosterone biosynthesis and metabolism Pathways and manipulation of testosterone biosynthesis and metabolism Dihydrotestosterone 8% Pregnenolone 3-βSD Progesterone 17- Pregnenolone 17a--lase 17-Progesterone 3-βSD 17a--lase Androstenedione DEA

More information

X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society

X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society 0021-972X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism rinted in U.S.A. Copyright 2000 by The Endocrine Society Effects of Testosterone Replacement in Hypogonadal Men*

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 1996, by the Massachusetts Medical Society VOLUME 335 J ULY 4, 1996 NUMBER 1 THE EFFECTS OF SUPRAPHYSIOLOGIC DOSES OF TESTOSTERONE ON MUSCLE SIZE AND STRENGTH

More information

TESTOSTERONE gel, for topical use, CIII Initial U.S. Approval: 1953

TESTOSTERONE gel, for topical use, CIII Initial U.S. Approval: 1953 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTOSTERONE gel safely and effectively. See full prescribing information for TESTOSTERONE gel. TESTOSTERONE

More information

pump. a metered-dose pump that delivers 30 mg of testosterone per twist. Each metered-dose pump is supplied with an applicator.

pump. a metered-dose pump that delivers 30 mg of testosterone per twist. Each metered-dose pump is supplied with an applicator. 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXIRON safely and effectively. See full prescribing information for AXIRON. AXIRON (testosterone)

More information

Androgen deficiency in the aging male

Androgen deficiency in the aging male Androgen deficiency in the aging male Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology The American Society for Reproductive

More information

PRESCRIBING INFORMATION

PRESCRIBING INFORMATION PRESCRIBING INFORMATION C DELATESTRYL* testosterone enanthate Solution for Injection, 200 mg/ml Androgens Valeant Canada LP 2150 Blvd. St-Elzear West Laval, Quebec H7L 4A8 Date of Revision: August 19,

More information

4.2 Posology, method and duration of administration

4.2 Posology, method and duration of administration The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in May 2011. 1. NAME OF MEDICINAL PRODUCT Testoviron Depot Oily solution for injection

More information

Boston University School of Public Health, Boston, Massachusetts; and 2 Charles R. Drew University of Medicine and Science, Los Angeles, California

Boston University School of Public Health, Boston, Massachusetts; and 2 Charles R. Drew University of Medicine and Science, Los Angeles, California Am J Physiol Endocrinol Metab 294: E1135 E1143, 2008. First published April 22, 2008; doi:10.1152/ajpendo.90213.2008. Effects of a supraphysiological dose of testosterone on physical function, muscle performance,

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25

More information

Figure 2. RESULTS DATA ANALYSIS

Figure 2. RESULTS DATA ANALYSIS ANDROGEN PARAMETERS IN HIRSUTE AND NORMAL FEMALE PATIENTS: IS THERE A ROLE FOR THE FREE ANDROGEN INDEX (FAI)? Castracane VD 1, Childress E 1, Tawwater B 1, Vankrieken L 2, El Shami AS 2 ( 1 Department

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION AVODART SOFT CAPSULES 0.5 MG 1. NAME OF THE MEDICINAL PRODUCT AVODART 0.5 mg capsules, soft. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For excipients, see 6.1.

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION AVODART SOFT CAPSULES 0.5 MG 1. NAME OF THE MEDICINAL PRODUCT Avodart 0.5 mg capsules, soft. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For excipients, see 6.1.

More information

Arthi Thirumalai 1, Kathryn E. Berkseth 1, John K. Amory 2

Arthi Thirumalai 1, Kathryn E. Berkseth 1, John K. Amory 2 REVIEW Treatment of Hypogonadism: Current and Future Therapies [version 1; referees: 2 approved] Arthi Thirumalai 1, Kathryn E. Berkseth 1, John K. Amory 2 1Division of Metabolism, Endocrinology, and Nutrition,

More information

Anavar For Sale Oxandrolone

Anavar For Sale Oxandrolone Anavar For Sale Oxandrolone Anavar (oxandrolone C 19 H 30 O 3 ) is an anabolic steroid that provides outstanding results. The Anavar steroid is a synthesized version of testosterone that boosts lean muscle

More information

2. Testosterone and Aging

2. Testosterone and Aging 2. Testosterone and Aging Shalender Bhasin, MD Thomas G. Travison, PhD Ravi Jasuja, PhD Carlo Serra, PhD Thomas W. Storer, PhD Shehzad Basaria, MD Case 2-1 A 78-year-old man requests evaluation for weakness,

More information

Andropause How Relevant?

Andropause How Relevant? Andropause How Relevant? 323 55 Andropause How Relevant? VN MISHRA, NALINI MISHRA INTRODUCTION In day-to-day practice it is not unusual to encounter male patients in their 50s or older who come to physician

More information

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Search for: Search Search High cholesterol icd 10 Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu High Cholesterol Diet Basics How to Lose Weight Fast icd 9 code for excess skin after weight

More information

Product Monograph. Sandoz Dutasteride

Product Monograph. Sandoz Dutasteride Product Monograph Pr Sandoz Dutasteride Dutasteride Capsules of 0.5 mg Type I and II 5 Alpha-reductase Inhibitor Sandoz Canada Inc. 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 Date of Preparation:

More information

Update on the use of dutasteride in the management of benign prostatic hypertrophy

Update on the use of dutasteride in the management of benign prostatic hypertrophy REVIEW Update on the use of dutasteride in the management of benign prostatic hypertrophy Joe Miller Thomas Tarter Division of Urology, Southern Illinois University School of Medicine, Springfield, IL,

More information

FULL PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. AVODART (dutasteride)

More information

Male pattern baldness is the most common type of balding among males. It affects roughly, 50% of men by the age of 50,

Male pattern baldness is the most common type of balding among males. It affects roughly, 50% of men by the age of 50, Dihydrotestosterone (DHT) Male pattern baldness is the most common type of balding among males. It affects roughly, 30% of men by the age of 30, 50% of men by the age of 50, 57% of men by the age of 60.

More information

Reproductive DHT Analyte Information

Reproductive DHT Analyte Information Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone

More information

WEIGHT LOSS DURING THE

WEIGHT LOSS DURING THE ORIGINAL CONTRIBUTION Testosterone Replacement and Resistance in HIV-Infected Men With Weight Loss and Low Testosterone Levels Shalender Bhasin, MD Thomas W. Storer, PhD Marjan Javanbakht, MPH Nancy Berman,

More information

PRODUCT INFORMATION REANDRON 1000

PRODUCT INFORMATION REANDRON 1000 PRODUCT INFORMATION REANDRON 1000 NAME OF THE MEDICINE Reandron 1000 is a hormonal preparation that contains 1000 mg testosterone undecanoate. The chemical name for testosterone undecanoate is (17β)-17-[(1-Oxoundecyl)oxy]-androst-4-

More information

Use of Performance Enhancing Substances Good Chemistry Gone Bad. Evan M. Klass, M.D., F.A.C.P.

Use of Performance Enhancing Substances Good Chemistry Gone Bad. Evan M. Klass, M.D., F.A.C.P. Use of Performance Enhancing Substances 2017 Good Chemistry Gone Bad Evan M. Klass, M.D., F.A.C.P. Doping the use of banned athletic performance-enhancing drugs by competitors Performance enhancing substances

More information

Testosterone administration to older men improves muscle function: molecular and physiological mechanisms

Testosterone administration to older men improves muscle function: molecular and physiological mechanisms Am J Physiol Endocrinol Metab 282: E60 E607, 2002. First published November ; 0.52/ajpendo.0062.200. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms

More information

Diabetes and Recreational Diving

Diabetes and Recreational Diving Guidelines for Diabetes and Recreational Diving Proceedings Summary DAN/UHMS Diabetes and Recreational Diving Workshop 1 Proceedings Summary DAN/UHMS Diabetes and Recreational Diving Workshop DAN.org Introduction

More information

population Completed double-blind 458 (67.7) 445 (65.0) study n (%)

population Completed double-blind 458 (67.7) 445 (65.0) study n (%) Study No: ARIA3002 Year 4 Title: A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression

More information

/00/$03.00/0 Vol. 141, No. 5

/00/$03.00/0 Vol. 141, No. 5 0013-7227/00/$03.00/0 Vol. 141, No. 5 Endocrinology Printed in U.S.A. Copyright 2000 by The Endocrine Society An Aged Rat Model of Partial Androgen Deficiency: Prevention of Both Loss of Bone and Lean

More information

Testosterone for Sale

Testosterone for Sale Testosterone for Sale Testosterone (C 19 H 28 O 2 ) is the male hormone. The brain, the pituitary gland, and the testes must work in perfect harmony to produce adequate amounts of it. If you want to know

More information

Andriol Testocaps. NAME OF THE MEDICINE: Testosterone undecanoate DESCRIPTION PRODUCT INFORMATION

Andriol Testocaps. NAME OF THE MEDICINE: Testosterone undecanoate DESCRIPTION PRODUCT INFORMATION PRODUCT INFORMATION Andriol Testocaps NAME OF THE MEDICINE: Testosterone undecanoate Testosterone undecanoate, the active ingredient of Andriol Testocaps, is a white to creamy-white crystalline powder.

More information

What do these athletes have in common?

What do these athletes have in common? What do these athletes have in common? Drugs in Sport Why do athletes cheat? 1988 Olympics 100m Final Why is this photo so iconic? 1988 Olympics 100m Final First time ever 4 of the 8 finalists run under

More information

Summary. Introduction. Dow Stough, MD

Summary. Introduction. Dow Stough, MD Original Contribution Blackwell Publishing ORIGINAL Inc CONTRIBUTION Dutasteride improves male pattern hair loss in a randomized study in identical twins Dow Stough, MD The Dermatology Clinic, Hot Springs,

More information

Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009

Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009 Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009 Charles J Ryan, MD Associate Professor of Clinical Medicine Helen Diller Family

More information

ELIGIBILITY REGULATIONS FOR THE FEMALE CLASSIFICATION (ATHLETES WITH DIFFERENCES OF SEX DEVELOPMENT) EXPLANATORY NOTES/Q&A

ELIGIBILITY REGULATIONS FOR THE FEMALE CLASSIFICATION (ATHLETES WITH DIFFERENCES OF SEX DEVELOPMENT) EXPLANATORY NOTES/Q&A What is the change? In April 2018, the IAAF issued new Eligibility Regulations for the Female Classification (Athlete with Differences of Sexual Development). These new Regulations, which come into effect

More information

New Zealand Data Sheet

New Zealand Data Sheet New Zealand Data Sheet 1. PRODUCT NAME TEROD 500 micrograms soft gelatin capsules. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 500 micrograms of dutasteride. For the full list of

More information

Evaluate the evidence for and against the use of testosterone to extend lifespan

Evaluate the evidence for and against the use of testosterone to extend lifespan 1 Evaluate the evidence for and against the use of testosterone to extend lifespan Background and introduction Testosterone is a steroid hormone which was first isolated in 1935 (David, Dingemanse, Freud

More information

Understanding combined oral contraception

Understanding combined oral contraception Understanding combined oral contraception Paula Briggs, FFSRH Consultant in Community Sexual and Reproductive Health Southport and Ormskirk NHS Hospital Trust May Logan Centre, Bootle, L20 5DQ paulaeb@aol.com

More information

Estudos.

Estudos. Estudos http://aformulabr.com.br/qrcode/oximetolonaafv01.pdf OXIMETOLONA Estimulador da hematopoese na anemia aplástica DESCRIÇÃO Oximetolona (17β-hidroxi-2-hidroximetileno-17α-metil-3-androstanona) é

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET NEW ZEALAND DATA SHEET 1. PRODUCT NAME DEPO-TESTOSTERONE 100mg/mL Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml solution for injection contains 100 mg/ml testosterone cypionate.

More information

Dutasteride Avodart Softgel Capsule

Dutasteride Avodart Softgel Capsule Dutasteride Avodart Softgel Capsule PRODUCT DESCRIPTION Dutasteride (Avodart ) is available as dull yellow, opaque, oblong soft gelatin capsules containing a clear, colourless to slightly yellow liquid.

More information

Risks Versus Benefits of Testosterone Therapy in Elderly Men

Risks Versus Benefits of Testosterone Therapy in Elderly Men REVIEW ARTICLE Drugs & Aging 1999 Aug; 15 (2): 131-142 1170-229X/99/0008-0131/$06.00/0 Adis International Limited. All rights reserved. Risks Versus Benefits of Testosterone Therapy in Elderly Men Shehzad

More information

CHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY. Ms. K. GOWRI. M.Pharm., Lecturer.

CHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY. Ms. K. GOWRI. M.Pharm., Lecturer. CHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY Ms. K. GOWRI. M.Pharm., Lecturer. Muscle Cell Metabolism Muscle Cells Provide ATP to Drive the Crossbridge Cycle The sources of ATP: Available ATP in the

More information

ATHLETE S BASIC PHYSIOLOGICAL PARAMETERS ENHANCED BY PRACTICING BREATHE TECHNIQUES OF YOGA IN DAILY LIFE SYSTEM

ATHLETE S BASIC PHYSIOLOGICAL PARAMETERS ENHANCED BY PRACTICING BREATHE TECHNIQUES OF YOGA IN DAILY LIFE SYSTEM ATHLETE S BASIC PHYSIOLOGICAL PARAMETERS ENHANCED BY PRACTICING BREATHE TECHNIQUES OF YOGA IN DAILY LIFE SYSTEM Tibor KÖKÉNY Abstract The physiological data of a swimmer were compared to the phases of

More information

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men Joel S. Finkelstein, M.D., Hang Lee, Ph.D., Sherri-Ann

More information

Antiduretic Hormone, Growth. Hormone & Anabolic Steroids

Antiduretic Hormone, Growth. Hormone & Anabolic Steroids Goudarz Sadeghi, DVM, PhD, DSc Associate Professor of Pharmacology University of Tehran Faculty of Veterinary Medicine Veterinary Pharmacology Endocrine System Antiduretic Hormone, Growth Hormone & Anabolic

More information

Hospital Admissions in the Northern Territory

Hospital Admissions in the Northern Territory Hospital Admissions in the Northern Territory 1976-28 www.healthynt.nt.gov.au Hospital Admissions in the Northern Territory, 1976 to 28 Shu Qin Li Sabine Pircher Steve Guthridge John Condon Jo Wright Acknowledgements

More information

1.) Take an alcohol swab to the stopper of both your peptide vial and the vial of the dilutent.

1.) Take an alcohol swab to the stopper of both your peptide vial and the vial of the dilutent. Peptide Guide Peptide Information Peptides come in the form of lyophilized (freeze dried) powder. The amount of powder/product is stated in International Units (IU's) or in Milligrams (mg). Melanotan peptides

More information

NATESTO Testosterone nasal gel 4.5% w/w

NATESTO Testosterone nasal gel 4.5% w/w PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION NATESTO Testosterone nasal gel 4.5% w/w Androgens Acerus Pharmaceuticals SRL Durants, Business Centre, Suite B Durants, Christ Church Barbados,

More information

HGH for Sale Human Growth Hormone

HGH for Sale Human Growth Hormone HGH for Sale Human Growth Hormone Many people consider HGH for sale, or Human Growth Hormone (C 990 H 1529 N 263 O 299 S 7 ) the fountain of youth. In fact, many experts suggest that this is the most sought-after

More information

WADA Technical Document TD2014EAAS. Endogenous Anabolic Androgenic Steroids Measurement and Reporting

WADA Technical Document TD2014EAAS. Endogenous Anabolic Androgenic Steroids Measurement and Reporting Endogenous Anabolic Androgenic Steroids Measurement and Reporting 1.0 Introduction The purpose of this Technical is to harmonize the approaches to the measurement and reporting of endogenous anabolic androgenic

More information

Testosterone Enanthate (Cas No ) Specification USP/BP. testosterone enanthate. Raw Material / Chemicals Index. Taj Pharmaceuticals Ltd.

Testosterone Enanthate (Cas No ) Specification USP/BP. testosterone enanthate. Raw Material / Chemicals Index. Taj Pharmaceuticals Ltd. Testosterone Enanthate (Cas No 315-37-7) Specification USP/BP Taj Active Pharmaceuticals Ingredients TAJCPG-DCYHEAPAZQ www.tajapi.com Raw Material / Chemicals Index Taj Pharmaceuticals Ltd. Testosterone

More information